Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2010-06-29

FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)

View source ↗

Summary

FDA approved a supplemental application for the methylphenidate transdermal system for attention-deficit/hyperactivity disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Methylphenidate Transdermal System (methylphenidate)

Snippet

SUPPL AP for METHYLPHENIDATE TRANSDERMAL SYSTEM (METHYLPHENIDATE)